Abstract
Atherosclerosis, the primary cause of cardiovascular disease, is a complex and multifactorial pathology resulted from the harmful interactions between genetic and environmental factors. There is a growing body of evidence in support of the role of mitochondrial factors in the pathogenesis of atherosclerosis. Impaired mitochondrial function and structural and qualitative changes in mitochondrial components such as mitochondrial DNA (mtDNA) damage may be directly involved in the development of multiple mechanisms of atherogenesis. Recent findings show that several heteroplasmic mutations of mtDNA are related to atherosclerosis, coronary heart disease and several atherosclerosis-related diseases such as arterial hypertension and diabetes mellitus. Therefore, heteroplasmic mtDNA mutations could represent a promising molecular biomarker of genetic susceptibility to atherosclerosis and related pathologies. This review is focused on the latest findings in the studies of mutations of mitochondrial genome, which are associated with atherosclerosis and atherosclerosis- related diseases.
Keywords: Atherosclerosis, atherogenesis, mitochondrial DNA, mutations, heteroplasmy, coronary heart disease.
Current Pharmaceutical Design
Title:Mutations of Mitochondrial DNA in Atherosclerosis and Atherosclerosis-Related Diseases
Volume: 21 Issue: 9
Author(s): Igor A. Sobenin, Andrey V. Zhelankin, Konstantin Y. Mitrofanov, Vasily V. Sinyov, Margarita A. Sazonova, Anton Y. Postnov and Alexander N. Orekhov
Affiliation:
Keywords: Atherosclerosis, atherogenesis, mitochondrial DNA, mutations, heteroplasmy, coronary heart disease.
Abstract: Atherosclerosis, the primary cause of cardiovascular disease, is a complex and multifactorial pathology resulted from the harmful interactions between genetic and environmental factors. There is a growing body of evidence in support of the role of mitochondrial factors in the pathogenesis of atherosclerosis. Impaired mitochondrial function and structural and qualitative changes in mitochondrial components such as mitochondrial DNA (mtDNA) damage may be directly involved in the development of multiple mechanisms of atherogenesis. Recent findings show that several heteroplasmic mutations of mtDNA are related to atherosclerosis, coronary heart disease and several atherosclerosis-related diseases such as arterial hypertension and diabetes mellitus. Therefore, heteroplasmic mtDNA mutations could represent a promising molecular biomarker of genetic susceptibility to atherosclerosis and related pathologies. This review is focused on the latest findings in the studies of mutations of mitochondrial genome, which are associated with atherosclerosis and atherosclerosis- related diseases.
Export Options
About this article
Cite this article as:
Sobenin A. Igor, Zhelankin V. Andrey, Mitrofanov Y. Konstantin, Sinyov V. Vasily, Sazonova A. Margarita, Postnov Y. Anton and Orekhov N. Alexander, Mutations of Mitochondrial DNA in Atherosclerosis and Atherosclerosis-Related Diseases, Current Pharmaceutical Design 2015; 21 (9) . https://dx.doi.org/10.2174/1381612820666141013133000
DOI https://dx.doi.org/10.2174/1381612820666141013133000 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide-Mediated Endothelial Dysfunction - Is there Need to Treat?
Current Vascular Pharmacology Soluble CD40L and its Role in Essential Hypertension: Diagnostic and Therapeutic Implications
Cardiovascular & Hematological Disorders-Drug Targets The L-Type Ca2+ Channel as a Therapeutic Target in Heart Disease
Current Medicinal Chemistry Production and Purification of Functional Lipids Through Enzymatic and Microorganism-Mediated Processes
Current Organic Chemistry Alpha-2 Agonists: Can they Modify the Outcomes in the Postanesthesia Care Unit?
Current Drug Targets Signaling Epicenters: The Role of Caveolae and Caveolins in Volatile Anesthetic Induced Cardiac Protection
Current Pharmaceutical Design Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development
Current Topics in Medicinal Chemistry Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry Targeting the Endothelial Ca2+ Toolkit to Rescue Endothelial Dysfunction in Obesity Associated-Hypertension
Current Medicinal Chemistry The Pleiotropic Effects of PPARs on Vascular Cells and Angiogenesis: Implications for Tissue Engineering
Current Stem Cell Research & Therapy Biomarkers for Diagnosing and Staging of Fabry Disease
Current Medicinal Chemistry The Renin-Angiotensin Systems: Evolving Pharmacological Perspectives for Cerebroprotection
Current Pharmaceutical Design Implications of Angiotensin II in Central Nervous System on Exercise Performance
Current Protein & Peptide Science Biomarkers in Molecularly Targeted Therapy for Cancer
Recent Patents on Biomarkers 25 Hydroxyvitamin D Levels are Negatively and Independently Associated with Fat Mass in a Cohort of Healthy Overweight and Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Curcumin Nanomicelle Improves Lipid Profile, Stress Oxidative Factors and Inflammatory Markers in Patients Undergoing Coronary Elective Angioplasty; A Randomized Clinical Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets Prevalence, Severity and Characteristics of Tardive Dyskinesia Among Schizophrenia Patients in an Israeli Psychiatric Center
Current Psychopharmacology Newly Diagnosed Dementia and Increased Risk of Hemorrhagic Stroke: A Nationwide Population-based Study
Current Alzheimer Research Obesity and Body Fat Distribution as Predictors for Obstructive Sleep Apnea Syndrome
Current Respiratory Medicine Reviews Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?
Current Vascular Pharmacology